Susquehanna International Group, LLP Biocryst Pharmaceuticals Inc Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

29 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $417,932 - $566,588	65,200 Added 64.75%	165,900 $1.26 Million
Q2 2024 Aug 15, 2024	SELL	$4.13 - $6.79 $1.08 Million - $1.77 Million	-260,700 Reduced 72.14%	100,700 $622,000
Q1 2024 May 07, 2024	SELL	$4.89 - $7.65 $1.73 Million - $2.71 Million	-354,000 Reduced 49.48%	361,400 $1.84 Million
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $460,650 - $626,225	-92,500 Reduced 11.45%	715,400 $4.29 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $1.33 Million - $1.57 Million	198,300 Added 32.53%	807,900 $5.72 Million
Q2 2023 Aug 11, 2023	SELL	$6.96 - $8.81 $2.07 Million - $2.62 Million	-296,900 Reduced 32.75%	609,600 $4.29 Million
Q1 2023 May 16, 2023	SELL	$7.94 - $11.84 $3.67 Million - $5.47 Million	-461,800 Reduced 33.75%	906,500 $7.56 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $4.71 Million - $6.37 Million	448,500 Added 48.76%	1,368,300 $15.7 Million
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $3.39 Million - $4.65 Million	-314,200 Reduced 25.46%	919,800 $11.6 Million
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $6.95 Million - $15.8 Million	-881,300 Reduced 41.66%	1,234,000 $13.1 Million
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $183,804 - $314,184	-15,900 Reduced 0.75%	2,115,300 $34.4 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $2.5 Million - $3.46 Million	223,900 Added 11.74%	2,131,200 $29.5 Million
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $5.02 Million - $6.24 Million	353,600 Added 22.76%	1,907,300 $27.4 Million
Q2 2021 Aug 11, 2021	BUY	$9.5 - $17.24 $4.16 Million - $7.54 Million	437,400 Added 39.18%	1,553,700 $24.6 Million
Q1 2021 May 17, 2021	BUY	$7.37 - $13.61 $6.33 Million - $11.7 Million	858,600 Added 333.18%	1,116,300 $11.4 Million
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $128,060 - $327,180	-38,000 Reduced 12.85%	257,700 $1.92 Million
Q3 2020 Nov 16, 2020	SELL	$3.43 - $5.53 $794,388 - $1.28 Million	-231,600 Reduced 43.92%	295,700 $1.02 Million
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $737,960 - $2.18 Million	388,400 Added 279.63%	527,300 $2.51 Million
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $192,480 - $494,433	120,300 Added 646.77%	138,900 $278,000
Q4 2019 Feb 14, 2020	SELL	$1.59 - $3.45 $54,855 - $119,025	-34,500 Reduced 64.97%	18,600 $64,000
Q3 2019 Nov 14, 2019	SELL	$2.5 - $3.73 $126,500 - $188,738	-50,600 Reduced 48.79%	53,100 $152,000
Q2 2019 Aug 14, 2019	SELL	$2.91 - $9.15 $513,033 - $1.61 Million	-176,300 Reduced 62.96%	103,700 $393,000
Q1 2019 May 15, 2019	BUY	$7.38 - $9.72 $1.48 Million - $1.95 Million	200,700 Added 253.09%	280,000 $2.28 Million
Q4 2018 Feb 14, 2019	BUY	$6.51 - $9.6 $106,764 - $157,440	16,400 Added 26.07%	79,300 $640,000
Q3 2018 Nov 14, 2018	SELL	$5.52 - $7.99 $425,039 - $615,230	-77,000 Reduced 55.04%	62,900 $480,000
Q2 2018 Aug 14, 2018	SELL	$4.6 - $6.52 $81,880 - $116,055	-17,800 Reduced 11.29%	139,900 $802,000
Q1 2018 May 15, 2018	BUY	$4.35 - $5.82 $261,869 - $350,364	60,200 Added 61.74%	157,700 $752,000
Q4 2017 Feb 14, 2018	BUY	$4.16 - $5.33 $134,784 - $172,692	32,400 Added 49.77%	97,500 $479,000
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $266,910 - $388,647	65,100	65,100 $341,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

Vanguard Group Inc Valley Forge, PA

20.3M
Shares

$154 Million
0.0% of portfolio
Black Rock Inc. New York, NY

20M
Shares

$151 Million
0.0% of portfolio
Avoro Capital Advisors LLC New York, NY

11.9M
Shares

$89.8 Million
1.36% of portfolio
Kynam Capital Management, LP Princeton, NJ

9.09M
Shares

$68.8 Million
5.66% of portfolio
State Street Corp Boston, MA

8.85M
Shares

$67 Million
0.0% of portfolio

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account